Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 31;71(12):1145–1153. doi: 10.1136/thoraxjnl-2015-207402

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

[¹⁸F] fluoromisonidazole ([¹⁸F]FMISO) PET-CT demonstrates increased tracer uptake within TB lesions. (A) [¹⁸F]FMISO PET-CT images. Transverse, coronal and sagittal slices through the [¹⁸F]FMISO target-to-background (TBR) and CT images of Patient 2. Top row, CT images show consolidation and a pulmonary cavity in the right upper lobe with a smaller, non-cavitating lesion in the left lung. Middle row, [¹⁸F]FMISO TBR map demonstrates intense uptake of tracer in the right upper lobe lesion and the liver, the site of metabolism of [¹⁸F]FMISO. Bottom row, coregistered CT and TBR images. (B) TBR values greater than unity were found for at least one lesion in all patients (each individual bar represents one region of interest, ROI).